Literature DB >> 26338824

miR-301a promotes intestinal mucosal inflammation through induction of IL-17A and TNF-α in IBD.

Chong He1, Yan Shi1, Ruijin Wu1, Mingming Sun1, Leilei Fang1, Wei Wu1,2, Changqin Liu1, Maochun Tang1, Zhong Li1, Ping Wang3, Yingzi Cong2,4, Zhanju Liu1.   

Abstract

OBJECTIVE: MicroRNA (miR)-301a is known to be involved in the tumourigenesis and pathogenesis of several autoimmune diseases, but it remains unclear whether miR-301a is associated with the pathogenesis of IBD.
METHODS: miR-301a expression was assessed in peripheral blood mononuclear cells (PBMC) and inflamed mucosa of patients with IBD by quantitative real-time-PCR. Peripheral blood CD4+ T cells were transduced with lentivirus-encoding pre-miR-301a (LV-miR-301a) or a reverse complementary sequence of miR-301a (LV-anti-miR-301a), and their differentiation and activation were investigated in vitro. Antisense miR-301a was administered into mice during trinitrobenzene sulphonic acid (TNBS)-induced colitis to determine its role in colitis.
RESULTS: miR-301a expression was significantly upregulated in PBMC and inflamed mucosa of patients with IBD compared with healthy controls. Stimulation with tumour necrosis factor-α (TNF-α) significantly enhanced miR-301a expression in IBD CD4+ T cells, which was markedly reversed by anti-TNF-α mAb (Infliximab) treatment. Transduction of LV-miR-301a into CD4+ T cells from patients with IBD promoted the Th17 cell differentiation and TNF-α production compared with the cells with expression of LV-anti-miR-301a. SNIP1 as a functional target of miR-301a was reduced in miR-301a expression but increased in LV-anti-miR-301a expression. Knockdown of SNIP1 could enhance Th17 cell differentiation. Furthermore, intracolonical administration of antisense miR-301a in TNBS-induced mouse colitis model significantly decreased numbers of interleukin (IL)-17A+ cells and amounts of pro-inflammatory cytokines (eg, IL-17A, TNF-α) in inflamed colon.
CONCLUSIONS: Our data reveal a novel mechanism in which the elevated miR-301a in PBMC and inflamed mucosa of IBD promotes Th17 cell differentiation through downregulation of SNIP1. Blockade of miR-301a in vivo may serve as a novel therapeutic approach in the treatment of IBD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  IBD BASIC RESEARCH; IMMUNOREGULATION; MUCOSAL IMMUNITY

Mesh:

Substances:

Year:  2015        PMID: 26338824     DOI: 10.1136/gutjnl-2015-309389

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  51 in total

Review 1.  Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease?

Authors:  Ross John Porter; Caroline Andrews; Daniel Paul Brice; Scott Kenneth Durum; Mairi Hall McLean
Journal:  Inflamm Bowel Dis       Date:  2018-09-15       Impact factor: 5.325

2.  Hypoxia inducible factor-1α-induced interleukin-33 expression in intestinal epithelia contributes to mucosal homeostasis in inflammatory bowel disease.

Authors:  M Sun; C He; W Wu; G Zhou; F Liu; Y Cong; Z Liu
Journal:  Clin Exp Immunol       Date:  2016-12-06       Impact factor: 4.330

3.  Smad nuclear interacting protein 1 (SNIP1) inhibits intestinal inflammation through regulation of epithelial barrier function.

Authors:  Y Shi; C He; C Ma; T Yu; Y Cong; W Cai; Z Liu
Journal:  Mucosal Immunol       Date:  2017-11-08       Impact factor: 7.313

Review 4.  Functional role and therapeutic targeting of microRNAs in inflammatory bowel disease.

Authors:  Artin Soroosh; Marina Koutsioumpa; Charalabos Pothoulakis; Dimitrios Iliopoulos
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-11-16       Impact factor: 4.052

5.  Probiotic Clostridium butyricum Improves the Growth Performance, Immune Function, and Gut Microbiota of Weaning Rex Rabbits.

Authors:  Lei Liu; Dong Zeng; Mingyue Yang; Bin Wen; Jing Lai; Yi Zhou; Hao Sun; Lvcheng Xiong; Jie Wang; Yicen Lin; Kangcheng Pan; Bo Jing; Ping Wang; Xueqin Ni
Journal:  Probiotics Antimicrob Proteins       Date:  2019-12       Impact factor: 4.609

Review 6.  MicroRNAs: how many in inflammatory bowel disease?

Authors:  Jeremy S Schaefer
Journal:  Curr Opin Gastroenterol       Date:  2016-07       Impact factor: 3.287

7.  MAdCAM-1 mediates retinal neuron degeneration in experimental colitis through recruiting gut-homing CD4+ T cells.

Authors:  Kun Peng; Jie Xiao; Jinxia Wang; Yaxin Song; Lianying Wu; Wenbo Xiu; Qinyuan Chen; Yanxi Chen; Ping Shuai; Chong He; Fang Lu
Journal:  Mucosal Immunol       Date:  2020-03-16       Impact factor: 7.313

8.  Vitamin D inhibits the Staphylococcal enterotoxin B-induced expression of tumor necrosis factor in microglial cells.

Authors:  Jinggui He; Xiyun Guo; Zhi-Qiang Liu; Ping-Chang Yang; Shaobo Yang
Journal:  Immunol Res       Date:  2017-08       Impact factor: 2.829

9.  MicroRNA-219a-5p suppresses intestinal inflammation through inhibiting Th1/Th17-mediated immune responses in inflammatory bowel disease.

Authors:  Yan Shi; Shenglan Dai; Caiyu Qiu; Tao Wang; Yong Zhou; Cuihua Xue; Jun Yao; Yaping Xu
Journal:  Mucosal Immunol       Date:  2019-10-18       Impact factor: 7.313

10.  MiRNA-29c-3p Promotes Intestinal Inflammation via Targeting Leukemia Inhibitory Factor in Ulcerative Colitis.

Authors:  Jian Guo; Ruiya Zhang; Yiqing Zhao; Junping Wang
Journal:  J Inflamm Res       Date:  2021-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.